Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized multicenter study of ITF2984 in active acromegaly
NL-OMON40166Phase 2Active, not recruiting
- Sponsor
- Italfarmaco
- Start
- Feb 2015
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ITF2984 and octreotide in acromegaly (4 arms), sponsored by Italfarmaco. Primary endpoint: Change in GH and/or IGF-1 levels. Started Feb 2015; status: active, not recruiting.
02
Drugs
ITF2984octreotide
03
Conditions
acromegaly
Beyond the preview
Go deeper on NL-OMON40166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40166.